Aarti Pharmalabs (AARTIPHARM) Share Price Falls 5.16% to Rs 822.85: What Today's Decline Shows

Aarti Pharmalabs Share Price fell to Rs 822.85 on 09 September 2026 at 11:22:47 AM IST, down 5.16% or Rs 44.75 from the previous close of Rs 867.60. With a market capitalisation of Rs 7,813.88 crore, the Mid Cap pharmaceuticals stock is drawing attention for a sharp session move.

The supplied data confirms the move, but it does not establish a company-specific catalyst for why the stock is falling today. What is clear is that it opened at Rs 863.85, touched an intraday high of Rs 872.05, and then moved down to a low of Rs 822.60 before trading near that level. That pattern points to sustained weakness through the session rather than a brief early dip.

For investors tracking Aarti Pharmalabs Share Price today, the key questions are how the stock behaves around current levels, whether valuation remains supported by profitability, and how its numbers compare with the wider Pharmaceuticals & Drugs industry. This analysis stays with verified price action, fundamentals, sector context and peer positioning rather than speculation.

Aarti Pharmalabs (AARTIPHARM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 822.85
Previous Close	Rs 867.6
Today's Move	-Rs 44.75 (-5.16%)
Open	Rs 863.85
High	Rs 872.05
Low	Rs 822.6
Turnover	Rs 2.19 crore
Market Capitalisation	Rs 7,813.88 crore
Market Cap Category	Mid Cap

Aarti Pharmalabs Share Price Today reflects a clear intraday decline. The stock moved from an open of Rs 863.85 to Rs 822.85 after touching a high of Rs 872.05 and a low of Rs 822.60. The session started only slightly below the previous close of Rs 867.60, but the later slide widened the loss to Rs 44.75, or 5.16%.

The narrow gap between the current price and the day low suggests the stock was trading near the weakest level of the session when this update was prepared. Turnover stood at Rs 2.19 crore, showing active value turnover, though the supplied data does not identify a specific corporate trigger. As a Mid Cap name in Healthcare, AARTIPHARM is large enough to be widely tracked but still sensitive to short-term sentiment shifts.

Aarti Pharmalabs (AARTIPHARM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 7,813.88 crore
P/E Ratio	36.91x
P/B Ratio	3.59x
ROE	8.5%
ROCE	10.77%
EPS	Rs 23.51
Book Value Per Share	Rs 241.54
Dividend Yield	0.4%

Aarti Pharmalabs is valued at Rs 7,813.88 crore with a P/E ratio of 36.91 and a P/B ratio of 3.59. Those multiples place the stock above book value by a meaningful margin, so the market is still assigning some premium to the business despite the current weakness.

That valuation needs to be read alongside returns. ROE is 8.50% and ROCE is 10.77%, while EPS stands at Rs 23.51 and book value per share is Rs 241.54. Dividend yield is 0.40%, which points to a modest payout profile rather than an income-led one.

The fundamental picture is mixed rather than extreme. Valuation is not at the highest end of the industry range, but profitability ratios are not especially strong versus benchmark levels. That balance helps explain why Aarti Pharmalabs Share Price is being watched closely in today’s session.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	36.91x
Benchmark Median P/E	32.19x
Benchmark Average P/E	49.13x
Benchmark P/E Range	3.39x to 668.68x
Company P/B Ratio	3.59x
Benchmark Median P/B	3.05x
Benchmark Average P/B	4.44x
Company ROE	8.5%
Benchmark Median ROE	11.82%
Benchmark Average ROE	11.12%
Company ROCE	10.77%
Benchmark Median ROCE	13.71%
Benchmark Average ROCE	13.62%
Company Market Capitalisation	Rs 7,813.88 crore
Benchmark Median Market Cap	Rs 715.6 crore
Benchmark Average Market Cap	Rs 14,150.82 crore

Aarti Pharmalabs operates in Healthcare and the Pharmaceuticals & Drugs industry, so its metrics are best read against the supplied same-industry benchmark. Across 201 companies, its P/E of 36.91 is above the median P/E of 32.19 but below the average of 49.13. Its P/B of 3.59 is also above the median of 3.05 and below the average of 4.44.

The company’s market capitalisation of Rs 7,813.88 crore is well above the same-industry median of Rs 715.6 crore, though below the average of Rs 14,150.82 crore. That places it meaningfully above many smaller listed pharma names, but still far from the industry’s biggest businesses.

Profitability is the more challenging comparison. ROE of 8.50% is below the benchmark median of 11.82% and average of 11.12%, while ROCE of 10.77% is below the median of 13.71% and average of 13.62%. So Aarti Pharmalabs Share Price is not at the richest end of sector valuation, but its returns also trail central industry levels.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,55,825.66	37.31	5.22	14.85	19.11
Divi's Laboratories	DIVISLAB	2,47,018.51	86.86	14.38	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,86,874.73	86.55	21.03	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,211.69	25.42	4.25	19.69	21.39
Cipla	CIPLA	1,12,773	33.17	3.18	11.83	16

The peer table highlights a major size gap. Aarti Pharmalabs, at Rs 7,813.88 crore market capitalisation, is far smaller than Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla.

On valuation, its P/E of 36.91 is close to Sun Pharma’s 37.31, above Zydus Lifesciences at 25.42 and Cipla at 33.17, but far below Divi's at 86.86 and Torrent at 86.55. Its P/B of 3.59 is slightly above Cipla’s 3.18, below Zydus at 4.25 and Sun Pharma at 5.22, and well below Divi's and Torrent.

The sharper gap is in profitability. Aarti Pharmalabs reports ROE of 8.50% and ROCE of 10.77%, both lower than every company in this peer set. Even in the wider benchmark list, Aurobindo Pharma’s ROE of 9.93% and ROCE of 12.76% remain ahead. That does not determine direction by itself, but it explains why the market may scrutinise valuation support more closely during a weak trading session.

Why Investors Are Watching Aarti Pharmalabs

• The stock fell 5.16% to Rs 822.85 from the previous close of Rs 867.60.
• Intraday trading weakened through the session, with the price near the day low of Rs 822.60.
• The company trades at 36.91 times earnings and 3.59 times book value.
• ROE of 8.50% and ROCE of 10.77% are below the same-industry medians of 11.82% and 13.71%.
• At Rs 7,813.88 crore market capitalisation, it remains a notable Mid Cap stock within Healthcare and Pharmaceuticals & Drugs.

About Aarti Pharmalabs

Aarti Pharmalabs is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. Based on the supplied classification, the company is tracked alongside listed pharma businesses whose performance is often assessed through valuation, profitability and market-cap positioning within the same industry universe.

That context matters because peer benchmarking is central in pharma analysis. Investors often compare P/E, P/B, ROE and ROCE across multiple companies to judge whether a stock price is supported by operating quality and balance-sheet efficiency.

Track Aarti Pharmalabs Share Price on Univest

UseAarti Pharmalabs (AARTIPHARM) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, investors can track Aarti Pharmalabs Share Price alongside daily price moves, market capitalisation, valuation ratios, profitability metrics, peer comparison and sector benchmarks.

Frequently Asked Questions

Why is Aarti Pharmalabs Share Price falling today?

Ans. Aarti Pharmalabs Share Price fell 5.16% to Rs 822.85 from the previous close of Rs 867.60. The supplied data confirms the decline, but it does not establish any company-specific catalyst behind today’s move.

What is the latest Aarti Pharmalabs Share Price Today?

Ans. Aarti Pharmalabs Share Price Today was Rs 822.85 at 11:22:47 AM IST on 09 September 2026. That placed the stock down Rs 44.75 for the day, reflecting a 5.16% decline versus the previous close.

What were the key intraday levels for Aarti Pharmalabs today?

Ans. The stock opened at Rs 863.85, touched a high of Rs 872.05 and fell to a low of Rs 822.60. Trading near Rs 822.85 means the price was close to the day’s weakest level.

What does today’s price action indicate for Aarti Pharmalabs?

Ans. Today’s price action shows weakness building during the session. The stock moved from Rs 863.85 at the open to Rs 822.85 later, and the small gap to the day low of Rs 822.60 suggests pressure persisted.

What is the market capitalisation of Aarti Pharmalabs?

Ans. Aarti Pharmalabs had a market capitalisation of Rs 7,813.88 crore in the supplied data. That places it in the Mid Cap category, larger than the same-industry median company but below major pharma leaders.

Is Aarti Pharmalabs expensive based on P/E and P/B?

Ans. Aarti Pharmalabs trades at a P/E of 36.91 and a P/B of 3.59. Its P/E is above the same-industry median of 32.19, while its P/B is above the median of 3.05 but below the average of 4.44.

How profitable is Aarti Pharmalabs compared with its industry?

Ans. The company’s ROE is 8.50% and ROCE is 10.77%. Both are below the same-industry medians of 11.82% and 13.71%, showing profitability trails central benchmark levels in Pharmaceuticals & Drugs. The stock belongs to the Healthcare sector.

What do EPS, book value and dividend yield show for Aarti Pharmalabs?

Ans. Aarti Pharmalabs reported EPS of 23.51, book value of Rs 241.54 and dividend yield of 0.40. Together, these metrics provide a view of earnings support, balance-sheet backing and historical payout relative to price.

How does Aarti Pharmalabs compare with large pharma peers?

Ans. Aarti Pharmalabs has a lower market capitalisation and weaker ROE and ROCE than peers such as Sun Pharma, Divi's, Torrent, Zydus and Cipla. Its P/E of 36.91 is moderate relative to that peer set.

What should investors monitor next in Aarti Pharmalabs stock news?

Ans. Investors should monitor whether the stock holds above today’s low of Rs 822.60, how valuation reacts to the 5.16% decline, and whether future updates improve confidence around profitability versus industry benchmarks.